D Knopman

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Neurobiol Aging 35:2096-106. 2014
  2. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
  3. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
  4. doi request reprint Alzheimer disease biomarkers and insights into mild cognitive impairment
    David S Knopman
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 80:978-80. 2013
  5. pmc Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012
  6. pmc Association of prior stroke with cognitive function and cognitive impairment: a population-based study
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 66:614-9. 2009
  7. pmc Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1843-9. 2009
  8. ncbi request reprint Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease
    D S Knopman
    The Mayo Alzheimer Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurology 65:986-90. 2005
  9. ncbi request reprint Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 65:876-81. 2005
  10. pmc Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia
    David S Knopman
    Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neuroepidemiology 34:34-42. 2010

Detail Information

Publications127 found, 100 shown here

  1. pmc 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA Electronic address
    Neurobiol Aging 35:2096-106. 2014
    ..The posterior cingulate and/or precuneus and lateral parietal regions have a unique vulnerability to reductions in glucose metabolic rate as a function both of age and carriage of an APOE ε4 allele...
  2. pmc Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis
    David S Knopman
    Mayo Clinic Alzheimer s Disease Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    JAMA Neurol 70:1030-8. 2013
    ....
  3. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
    ..With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders...
  4. doi request reprint Alzheimer disease biomarkers and insights into mild cognitive impairment
    David S Knopman
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 80:978-80. 2013
    ..However, knowledge of cognitive and functional status in MCI still leaves much uncertainty regarding the ability to predict worsening...
  5. pmc Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012
    ..Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity...
  6. pmc Association of prior stroke with cognitive function and cognitive impairment: a population-based study
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 66:614-9. 2009
    ..Defining the nature of the contribution of stroke to cognitive impairment remains challenging...
  7. pmc Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1843-9. 2009
    ..Because there is only limited longitudinal imaging data currently available, we measured the rate of change over 1 year of whole brain volume (WBV) and ventricular volume (VV) in patients with FTLD...
  8. ncbi request reprint Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease
    D S Knopman
    The Mayo Alzheimer Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurology 65:986-90. 2005
    ..To study coronary artery bypass grafting (CABG) as a risk factor for dementia and Alzheimer disease (AD) using a case-control design...
  9. ncbi request reprint Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 65:876-81. 2005
    ..Because cardiovascular (CV) risk factors have been associated with declines in cognitive functions and late life dementia, CV risk factors should also be associated with brain atrophy...
  10. pmc Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia
    David S Knopman
    Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neuroepidemiology 34:34-42. 2010
    ..The telephone assessment of cognitive functions may reduce the cost and burden of epidemiological studies...
  11. pmc Invited commentary: Albuminuria and microvascular disease of the brain--a shared pathophysiology
    David S Knopman
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Epidemiol 171:287-9; author reply 290-1. 2010
    ....
  12. pmc Vascular risk factors: imaging and neuropathologic correlates
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Alzheimers Dis 20:699-709. 2010
    ..The role of vascular risk factors in midlife should be the focus of public health efforts to reduce the burden of late-life cognitive impairment...
  13. ncbi request reprint Current treatment of mild cognitive impairment and Alzheimer's disease
    David S Knopman
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Neurol Neurosci Rep 6:365-71. 2006
    ..Several new agents targeted directly at amyloid beta peptide production are currently in clinical trials, but no large studies have been reported over the past year...
  14. ncbi request reprint Dementia and cerebrovascular disease
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:223-30. 2006
    ..The overlap between cerebrovascular disease and Alzheimer disease produces a disorder that might be amenable to therapeutic approaches based on either mechanism...
  15. ncbi request reprint Incidence and causes of nondegenerative nonvascular dementia: a population-based study
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Arch Neurol 63:218-21. 2006
    ..Information on the incidence of nondegenerative and nonvascular dementia is limited...
  16. doi request reprint Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study
    David S Knopman
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
    Alzheimers Dement 5:207-14. 2009
    ..Strokes, vascular risk factors, and apolipoprotein E (APOE) genotype are associated with cognitive decline in the elderly, but definitive evidence that these affect cognition as early as middle age is limited...
  17. pmc Clinical trial design issues in mild to moderate Alzheimer disease
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Cogn Behav Neurol 21:197-201. 2008
    ..The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease...
  18. pmc Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
    David S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain 131:2957-68. 2008
    ..There are several candidate outcome measures -- including the FTLD-CDR and the cognitive composites -- that could be used in clinical trials across the spectrum of FTLD...
  19. doi request reprint Cerebrovascular disease and dementia
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Radiol 80:S121-7. 2007
    ..Although advances in imaging have increased our recognition of cerebrovascular disease in the elderly, vascular dementia is still inadequately recognized in clinical practice...
  20. ncbi request reprint Longitudinal tracking of FTLD: toward developing clinical trial methodology
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Alzheimer Dis Assoc Disord 21:S58-63. 2007
    ..In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored...
  21. ncbi request reprint Incident dementia in women is preceded by weight loss by at least a decade
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 69:739-46. 2007
    ..Although several studies reported weight loss preceding the onset of dementia, other studies suggested that obesity in midlife or even later in life may be a risk factor for dementia...
  22. ncbi request reprint The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 62:506-8. 2004
    ..The incidence rates (new cases per 100,000 person-years) were 2.2 for ages 40 to 49, 3.3 for ages 50 to 59, and 8.9 for ages 60 to 69. For comparison, the corresponding rates for Alzheimer disease were 0.0, 3.3, and 88.9...
  23. ncbi request reprint Pharmacotheraphy for Alzheimer's disease
    D Knopman
    Department of Neurology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Neurol Neurosci Rep 1:428-34. 2001
    ..Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed...
  24. ncbi request reprint Development and standardization of a new telephonic cognitive screening test: the Minnesota Cognitive Acuity Screen (MCAS)
    D S Knopman
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neuropsychiatry Neuropsychol Behav Neurol 13:286-96. 2000
    ....
  25. pmc Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships
    David S Knopman
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, United States
    J Neurol Sci 271:53-60. 2008
    ..Because of similarities between brain and kidney microvascular disease, there may be a relationship between measures of renal microvascular disease and brain structural changes in middle aged or elderly individuals...
  26. ncbi request reprint Incidence of vascular dementia in Rochester, Minn, 1985-1989
    David S Knopman
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester MN 55905, USA
    Arch Neurol 59:1605-10. 2002
    ..To examine the contribution of cerebrovascular disease to dementia...
  27. ncbi request reprint Survival study of vascular dementia in Rochester, Minnesota
    David S Knopman
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Arch Neurol 60:85-90. 2003
    ..To investigate the relationship between features and definitions of vascular dementia (VaD) and survival...
  28. pmc Estimating the number of persons with frontotemporal lobar degeneration in the US population
    David S Knopman
    Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Mol Neurosci 45:330-5. 2011
    ..The main threat to the accuracy of the estimates is the difficulty in diagnosing the clinical syndromes that comprise the FTLD group of disorders...
  29. ncbi request reprint Pharmacotherapy for Alzheimer's disease: 2002
    David Knopman
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Neuropharmacol 26:93-101. 2003
    ..Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed...
  30. ncbi request reprint Vascular dementia in a population-based autopsy study
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Arch Neurol 60:569-75. 2003
    ..The validity of the clinical diagnosis of vascular dementia (VaD) remains suboptimal...
  31. pmc Language and behavior domains enhance the value of the clinical dementia rating scale
    David S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 7:293-9. 2011
    ..The CDRstd does not specifically address language dysfunction or alteration in personality and social behaviors which are prominent in behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA)...
  32. pmc Passive case-finding for Alzheimer's disease and dementia in two U.S. communities
    David S Knopman
    Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 7:53-60. 2011
    ..In this article, the advantages and disadvantages of passive case-finding were discussed, and the following conclusion was drawn: the purpose of the study being conducted should determine the case-finding approach that is to be used...
  33. ncbi request reprint Neuropathology of cognitively normal elderly
    D S Knopman
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Neuropathol Exp Neurol 62:1087-95. 2003
    ..The few subjects with more severe AD pathology can be expected based on incidence rates of AD in the very elderly...
  34. pmc Vascular risk factors and longitudinal changes on brain MRI: the ARIC study
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 76:1879-85. 2011
    ....
  35. ncbi request reprint Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey-Osterrieth Complex Figure
    M M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Exp Neuropsychol 29:377-84. 2007
    ..Limitations and unique features of the MOANS normative data are also discussed...
  36. pmc DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:902-4. 2005
    ..002). Magnetic resonance diffusion-weighted imaging may help identify patients with aMCI who will progress to AD as well as or better than structural MRI measures of hippocampal atrophy...
  37. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:294-301. 2009
    ....
  38. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:287-93. 2009
    ..To assess the correlations of both MRI and CSF biomarkers with clinical diagnosis and with cognitive performance in cognitively normal (CN) subjects and patients with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD)...
  39. pmc Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients
    M M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 61:500-6. 2003
    ..To determine whether an fMRI memory encoding task distinguishes among cognitively normal elderly individuals, patients with mild cognitive impairment (MCI), and patients with early Alzheimer's disease (AD)...
  40. ncbi request reprint DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging
    T J Ferman
    Department of Psychiatry and Psychology, Mayo Clinic and Foundation, Jacksonville, FL 32224, USA
    Neurology 62:181-7. 2004
    ..To determine whether certain aspects of fluctuations reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) and normal aging...
  41. pmc Serial MRI and CSF biomarkers in normal aging, MCI, and AD
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 75:143-51. 2010
    ..Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials...
  42. pmc Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study
    S R Lesage
    University of Maryland Medical Center, Department of Neurology, 22 S Greene St, Baltimore, MD 21201, USA
    Neurology 73:862-8. 2009
    ..To better understand the role of SVD in cognitive function, we investigated the relationship between retinal microvascular abnormalities and longitudinal changes in cognitive function in a community-based study...
  43. pmc MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 70:512-20. 2008
    ..To compare the patterns of gray matter loss in subjects with amnestic mild cognitive impairment (aMCI) who progress to Alzheimer disease (AD) within a fixed clinical follow-up time vs those who remain stable...
  44. ncbi request reprint Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology
    G A Rippon
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurocase 11:204-11. 2005
    ..We suggest that PSP with or without coexisting AD and AGD be included in the differential diagnosis of patients presenting with FTD...
  45. pmc MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN, USA
    Neurology 60:253-60. 2003
    ..To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in a therapeutic trial for AD...
  46. ncbi request reprint Cardiovascular risk factors and cognitive decline in middle-aged adults
    D Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 56:42-8. 2001
    ..Interventions aimed at hypertension or diabetes that begin before age 60 might lessen the burden of cognitive impairment in later life...
  47. ncbi request reprint Mild cognitive impairment in the oldest old
    B Boeve
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 60:477-80. 2003
    ..No data exist on whether the syndrome of amnestic mild cognitive impairment occurs in the oldest old, or if the relationships for functional status and neuropsychometric performance based on clinical diagnosis hold true in this age group...
  48. pmc 1H MR spectroscopy in common dementias
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    Neurology 63:1393-8. 2004
    ..To determine the 1H MR spectroscopic (MRS) findings and intergroup differences among common dementias: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD)...
  49. pmc Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies
    T J Ferman
    Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL 32224, USA
    Neurology 77:875-82. 2011
    ..To determine whether adding REM sleep behavior disorder (RBD) to the dementia with Lewy bodies (DLB) diagnostic criteria improves classification accuracy of autopsy-confirmed DLB...
  50. pmc Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1058-65. 2009
    ..To use a case-control study to assess and compare patterns of gray matter loss across groups of subjects with different mutations in the microtubule-associated protein tau (MAPT) gene...
  51. pmc MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology
    K Kantarci
    Departmentsof Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:771-8. 2010
    ..To determine the proton magnetic resonance spectroscopy ((1)H MRS) changes in carriers of microtubule-associated protein (MAPT) mutations in a case-control study...
  52. pmc Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
    E McDade
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:1245-9. 2012
    ..To report the phenotypic characterization of monozygotic twins with mutations encoding progranulin (PGRN)...
  53. ncbi request reprint An overview of common non-Alzheimer dementias
    D S Knopman
    Department of Neurology, Mayo Medical School, Rochester, Minnesota, USA
    Clin Geriatr Med 17:281-301. 2001
    ..At least some of the frontotemporal dementias, which in this article encompass the progressive aphasias, have mutations in the tau gene that account for some of the phenotypic variations...
  54. pmc MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 71:743-9. 2008
    ..We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology...
  55. ncbi request reprint Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy
    D F Tang-Wai
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 63:1168-74. 2004
    ..To examine the clinical, genetic, and neuropathologic features of posterior cortical atrophy (PCA)...
  56. ncbi request reprint An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
    D Knopman
    Department of Neurology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    Alzheimer Dis Assoc Disord 15:162-5. 2001
    ..The current study provides a basis for pursuing larger controlled trials with betaine in AD. The homocysteine to S-adenosylmethionine pathway is of interest in AD therapeutics...
  57. pmc Atrophy rates accelerate in amnestic mild cognitive impairment
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 70:1740-52. 2008
    ..We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN)...
  58. pmc Effects of age on the glucose metabolic changes in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    AJNR Am J Neuroradiol 31:1247-53. 2010
    ..Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI...
  59. pmc Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester MN 55905, USA
    Neurology 74:1279-87. 2010
    ..To use diffusion tensor imaging (DTI) to assess gray matter and white matter tract diffusion in behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SMD), and progressive nonfluent aphasia (PNFA)...
  60. pmc Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI
    K Kantarci
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 74:1814-21. 2010
    ....
  61. pmc Two distinct subtypes of right temporal variant frontotemporal dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1443-50. 2009
    ..We aimed to determine whether right temporal FTD is a homogeneous clinical, imaging, and pathologic/genetic entity...
  62. pmc Progressive aphasia secondary to Alzheimer disease vs FTLD pathology
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:25-34. 2008
    ..The pathology causing progressive aphasia is typically a variant of frontotemporal lobar degeneration, especially with ubiquitin-positive inclusions (FTLD-U). Less commonly the underlying pathology is Alzheimer disease (AD)...
  63. pmc Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 65:1227-31. 2005
    ....
  64. pmc Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:1850-7. 2008
    ....
  65. ncbi request reprint Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia
    K A Josephs
    Department of Neurology, Division of Behavioural Neurology, Mayo Clinic, Mayo Foundation, Rochester, MN 55905, USA
    Neurocase 11:283-96. 2005
    ..These cases demonstrate that atypical PSP can present as AOS and PNFA without the classic features of PSP...
  66. ncbi request reprint Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND
    K A Josephs
    Department of Neurology, Mayo Clinic, 200 First St S W, Rochester, MN 55905, USA
    Neurology 65:645-7. 2005
    ..An analysis of patient outcomes in these cases reveals that FTLD-MND has significantly shorter survival than FTLD-U, suggesting that FTLD-MND is a more aggressive disease process...
  67. ncbi request reprint Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP
    K A Josephs
    Division of Movement Disorders, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 66:41-8. 2006
    ..To examine the relationship between early clinical features, pathologies, and biochemistry of the frontotemporal lobar degenerations (FTLDs), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)...
  68. pmc Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
    C R Jack
    Department of Diagnostic Radiology and MR Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 62:591-600. 2004
    ....
  69. ncbi request reprint A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?
    G E Smith
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 69:133-9. 2007
    ..To compare logistic and bilogistic models to describe the pattern of cognitive decline in the preclinical phase of Alzheimer disease (AD)...
  70. pmc The anatomic correlate of prosopagnosia in semantic dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 71:1628-33. 2008
    ..To determine the anatomic correlate of prosopagnosia in subjects with semantic dementia...
  71. pmc Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
    ..To investigate the combined ability of hippocampal volumes, 1H magnetic resonance spectroscopy (MRS) metabolites, and cerebrovascular disease to predict the risk of progression to dementia in mild cognitive impairment (MCI)...
  72. pmc TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers
    N Finch
    Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Neurology 76:467-74. 2011
    ....
  73. pmc Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:2212-20. 2010
    ..To determine whether TDP-43 type is associated with distinct patterns of brain atrophy on MRI in subjects with pathologically confirmed frontotemporal lobar degeneration (FTLD)...
  74. pmc Imaging correlates of pathology in corticobasal syndrome
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Neurology 75:1879-87. 2010
    ..The aim of this study was to determine whether patterns of atrophy on imaging could be useful to help predict underlying pathology in CBS...
  75. pmc Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging
    R C Petersen
    Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 75:889-97. 2010
    ..We investigated the prevalence of mild cognitive impairment (MCI) in Olmsted County, MN, using in-person evaluations and published criteria...
  76. ncbi request reprint Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, Minneapolis, MN 55905, USA
    Neurology 61:40-5. 2003
    ..To determine if synucleinopathy pathology is related to REM sleep behavior disorder (RBD) plus dementia or parkinsonism...
  77. pmc Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN
    J L Whitwell
    Department of Radiology Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 72:813-20. 2009
    ..To compare patterns of gray matter loss in subjects with mutations in the progranulin (PGRN) gene to subjects with mutations in the microtubule-associated protein tau (MAPT) gene...
  78. ncbi request reprint A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial
    J Quinn
    Department of Neurology, Portland Veteran s Affairs Medical Center, P3 R and D, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Neurology 58:433-7. 2002
    ..The global impression of a clinician is an Food and Drug Administration--mandated primary outcome measure for clinical trials in dementia. Reliability and validity of these measures are not well established...
  79. ncbi request reprint Vascular dementia: clinical, neuroradiologic and neuropathologic aspects
    M E Murray
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Panminerva Med 49:197-207. 2007
    ..VaD is an entity that provides many challenges to the clinician, neuroradiologist and neuropathologist in part because evidence-based studies often lack clear definitions of the disease...
  80. ncbi request reprint Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
    D S Knopman
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 56:1143-53. 2001
    ..To update the 1994 practice parameter for the diagnosis of dementia in the elderly...
  81. pmc The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics
    Rosebud O Roberts
    Division of Epidemiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neuroepidemiology 30:58-69. 2008
    ..The objective of this study was to establish a prospective population-based cohort to investigate the prevalence, incidence and risk factors for mild cognitive impairment (MCI) and dementia...
  82. ncbi request reprint Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia
    David S Knopman
    Department of Neurology and Alzheimer s Disease Research Center, Mayo Clinic, Rochester Minn 55905, USA
    Mayo Clin Proc 78:1290-308. 2003
    ..As new treatments become available for Alzheimer disease, the most common of the dementias, accurate diagnosis allows the appropriate patients to receive treatment...
  83. ncbi request reprint Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study
    Yonas E Geda
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Arch Neurol 63:435-40. 2006
    ..It remains unknown whether depression and apolipoprotein E genotype are risk factors for incident mild cognitive impairment (MCI)...
  84. ncbi request reprint Association of ambulatory blood pressure with ischemic brain injury
    Gary L Schwartz
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hypertension 49:1228-34. 2007
    ..009 for each). Higher ambulatory blood pressure levels and a nondipping circadian pattern contribute to greater leukoaraiosis volume after controlling for office blood pressure...
  85. pmc 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 8:934-42. 2002
    ..Among 1H-MRS measurements, the NAA/MI ratio maybe the most efficient predictor of memory and cognitive function in patients with MCI and AD...
  86. ncbi request reprint Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T
    Kejal Kantarci
    Department of Diagnostic Radiology, Milwaukee, WI, USA
    AJNR Am J Neuroradiol 24:843-9. 2003
    ..5 and 3 T to diagnostically discriminate among cognitively normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD)...
  87. ncbi request reprint Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study
    Valory N Pavlik
    Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77005, USA
    Am J Epidemiol 157:327-34. 2003
    ..97; hazard ratio 7-point DSST score increment = 0.86, 95% confidence interval: 0.80, 0.93). Cognitive function measured in middle age appears to have prognostic importance for life expectancy similar to that reported in elderly adults...
  88. ncbi request reprint Cognitive function predicts first-time stroke and heart disease
    Jacob S Elkins
    University of California, San Francisco, CA 94143, USA
    Neurology 64:1750-5. 2005
    ..To investigate whether impaired cognitive function is an early manifestation of vascular injury in the brain and therefore predicts risk of subsequent cardiovascular disease...
  89. pmc Rates of cerebral atrophy differ in different degenerative pathologies
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Brain 130:1148-58. 2007
    ....
  90. ncbi request reprint Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 61:1881-4. 2004
    ..Various pathologic findings, including corticobasal degeneration (CBD), progressive supranuclear palsy, and frontotemporal degenerations, underlie CBS...
  91. ncbi request reprint Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment
    David F Tang-Wai
    Department of Neurology, the Mayo Alzheimer s Disease Research Center, Mayo Clinic, Rochester, Minn 55905, USA
    Arch Neurol 60:1777-81. 2003
    ..The Short Test of Mental Status (STMS) was specifically developed for use in dementia assessment and was intended to be more sensitive to problems of learning and mental agility that may be seen in mild cognitive impairment (MCI)...
  92. ncbi request reprint De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI)
    Yonas E Geda
    Department of Psychiatry and Psychology, Mayo Clinic Rochester, MN 55905, USA
    Int Psychogeriatr 16:51-60. 2004
    ..There is inadequate information regarding the neuropsychiatric aspect of Mild Cognitive Impairment (MCI)...
  93. ncbi request reprint Heart disease and dementia: a population-based study
    Francesca Bursi
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN55905, USA
    Am J Epidemiol 163:135-41. 2006
    ..82, 95% CI: 0.70, 0.95; p = 0.010). There was no evidence of a positive association between dementia and preceding myocardial infarction, while there was a decreased risk of myocardial infarction and cardiac death following dementia...
  94. ncbi request reprint Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:506-12. 2006
    ..The ability to detect the clinical signs of dementia and motor neuron disease in pathologically confirmed FTLD-MND has not been assessed...
  95. pmc Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study
    Yonas E Geda
    Department of Psychiatry and Psychology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Gen Psychiatry 65:1193-8. 2008
    ..Little is known about the population-based prevalence of neuropsychiatric symptoms in mild cognitive impairment (MCI)...
  96. pmc 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Brain 130:1777-86. 2007
    ..These results also suggest that 3D patterns of grey matter atrophy may help to predict the time to the first diagnosis of AD in subjects with aMCI...
  97. ncbi request reprint Alzheimer's disease patients' cognitive status and course years prior to symptom recognition
    Jane H Cerhan
    Mayo Clinic College of Medicine Rochester, Minnesota, USA
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 14:227-35. 2007
    ..A significant interaction (but no group effect) was seen for verbal comprehension...
  98. pmc Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 29:1285-95. 2008
    ..000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI...
  99. ncbi request reprint MCI is a clinically useful concept
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int Psychogeriatr 18:394-402; discussion 409-14. 2006
  100. pmc Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations
    Jennifer L Whitwell
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:371-6. 2007
    ..Mutations in the progranulin gene (PGRN) have recently been identified as a cause of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) in some families...
  101. ncbi request reprint Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
    Neill R Graff-Radford
    Department of Neuroscience, Mayo College of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Arch Neurol 64:354-62. 2007
    ..To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease...

Research Grants4

  1. Frontotemporal degeneration: a basis for clinical trials
    David Knopman; Fiscal Year: 2003
    ..abstract_text> ..
  2. Frontotemporal degeneration: a basis for clinical trials
    David Knopman; Fiscal Year: 2004
    ..abstract_text> ..
  3. Frontotemporal degeneration: a basis for clinical trials
    David Knopman; Fiscal Year: 2005
    ..abstract_text> ..
  4. Frontotemporal degeneration: a basis for clinical trials
    David Knopman; Fiscal Year: 2006
    ..abstract_text> ..